von Tobias Borgers | Nov 6, 2019 | Glaxo
Issued: London,UK ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced today that 17 abstracts from its portfolio of late-stage pipeline and approved HIV treatments will be presented...
von Tobias Borgers | Nov 6, 2019 | Boehringer
The Veterinary Drugs Market 2020: Recent research report presented by Market.us deeply analyses important options like recent trends and current scenario as well as future growth potential of market dynamics in various geographic segments for this business landscape...
von Tobias Borgers | Nov 5, 2019 | Boehringer
Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, inaugurated on Monday its new office in Cairo.
„The company has had a presence in Egypt through a scientific office, and its new office marks the launch of its new commercial...
von Tobias Borgers | Nov 2, 2019 | Merck
Pharmamarktstudie 2019 der Firmen Merck, AbbVie, Novartis, Roche, GlaxoSmithKline EUWID Facility Management Link zum Originalbeitrag
von Tobias Borgers | Okt 31, 2019 | Roche
Media Release Basel, 06 February 2019 Roche joins the World Federation of Hemophilia Humanitarian Aid Program Hemlibra donation will provide prophylactic treatment to as many as 1,000 people with haemophilia A over five years in countries where there is little or no...
von Tobias Borgers | Okt 27, 2019 | Bayer
Some credit Bayer AG (XTER: BAYN) with making the worst corporate deal in recent memory. With a market cap of about $62 billion, the German conglomerate’s value is below what it paid for Monsanto last year. Even Houdini would have a difficult time making the...
